Adalimumab was more effective in the patients with bio-naive and early Crohn's disease

被引：0
|
作者：
Hisamatsu, T. [1 ]
Matsuoka, K. [1 ]
Naganuma, M. [2 ]
Miyoshi, J. [1 ,3 ]
Inoue, N. [4 ]
Yajima, T. [1 ]
Mizuno, S. [1 ]
Saigusa, K. [1 ]
Nakazato, Y. [1 ]
Mori, K. [1 ]
Takeshita, K. [1 ]
Nanki, K. [1 ]
Kiyohara, H. [1 ]
Iwao, Y. [4 ]
Ogata, H. [2 ]
Kanai, T. [1 ]
机构：
[1] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan
[2] Keio Univ, Ctr Diagnost & Therapeut Endoscopy, Tokyo, Japan
[3] Tokyo Dent Univ, Ichikawa Gen Hosp, Dept Internal Med, Ichikawa, Japan
[4] Keio Univ, Ctr Prevent Med, Tokyo, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60689-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P569
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [31] Adalimumab maintenance therapy is cost effective for maintaining remission in patients with Crohn's disease
    Feagan, Brian
    Loftus, Edward
    Johnson, Scott
    Wu, Eric
    Yu, Andrew
    Chao, Jingdong
    Mulani, Parvez
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S383 - S383
  • [32] Adalimumab - An effective and promising treatment for patients with fistulizing Crohn's disease: A case series
    Kouklakis G.
    Efremidou E.I.
    Zezos P.
    Liratzopoulos N.
    Souftas V.D.
    Gatopoulou A.
    Simopoulos K.
    Manolas K.J.
    Journal of Medical Case Reports, 5 (1)
  • [33] Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab
    Duveau, Nicolas
    Nachury, Maria
    Gerard, Romain
    Branche, Julien
    Maunoury, Vincent
    Boualit, Medina
    Wils, Pauline
    Desreumaux, Pierre
    Pariente, Benjamin
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (02) : 163 - 169
  • [34] Adalimumab Dose Escalation Is Effective and Well Tolerated in Crohn's Disease Patients With Secondary Loss of Response to Adalimumab
    Duveau, Nicolas
    Nachury, Maria
    Boualit, Medina
    Gerard, Romain
    Branche, Julien
    Maunoury, Vincent
    Desreumaux, Pierre
    Pariente, Benjamin
    GASTROENTEROLOGY, 2016, 150 (04) : S813 - S814
  • [35] Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab
    Duveau, N.
    Nachury, M.
    Boualit, M.
    Gerard, R.
    Branche, J.
    Maunoury, V.
    Desreumaux, P.
    Pariente, B.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S320 - S320
  • [36] A propensity score-matched comparison of infliximab and adalimumab in naive and nonnaive patients with Crohn's disease
    Orlando, A.
    Macaluso, F. S.
    Fries, W.
    Privitera, A. C.
    Cappello, M.
    Siringo, S.
    Inserra, G.
    Magnano, A.
    Di Mitri, R.
    Belluardo, N.
    Scarpulla, G.
    Magri, G.
    Trovatello, N.
    Carroccio, A.
    Genova, S.
    Bertolami, C.
    Vassallo, R.
    Ventimiglia, M.
    Renna, S.
    Orlando, R.
    Rizzuto, G.
    Cottone, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S399 - S399
  • [37] A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in pediatric patients with Crohn's disease
    Driban, G.
    Matar, M.
    Lev-Tzion, R.
    Ledder, O.
    Granot, M.
    Yerushalmy-Feler, A.
    Magen-Rimon, R.
    Zifman, E.
    Turner, D.
    Assa, A.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1774 - i1774
  • [38] Effectiveness of Adalimumab in Perianal Fistulas in Crohn's Disease Patients Naive to Anti-TNF Therapy
    Castano-Milla, Carlos
    Chaparro, Maria
    Saro, Cristina
    Barreiro-de Acosta, Manuel
    Garcia-Albert, Ana M.
    Bujanda, Luis
    Martin-Arranz, Maria D.
    Carpio, Daniel
    Munoz, Fernando
    Mancenido, Noemi
    Garcia-Planella, Esther
    Piqueras, Marta
    Calvet, Xavier
    Cabriada, Jose L.
    Botella, Belen
    Bermejo, Fernando
    Gisbert, Javier P.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (01) : 34 - 40
  • [39] Adalimumab in Crohn's disease
    Van Assche, Gert
    Vermeire, Severine
    Rutgeerts, Paul
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04): : 355 - 365
  • [40] Adalimumab for Crohn's disease
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 291 - 291
12345